Reading AXON? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AXON free→Reading AXON? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AXON free→
NASDAQIndustrialsAerospace & DefenseSnapshot 2026-06-12
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality is fragile, and management's track record is volatile. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, AXON is typical. Peer multiples imply a price about 51% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 5 valuation methods, at three horizons. Current price $441.73. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $442 the market pays 63× p/e — above the 38× p/e peer median but in line with its own 70× history. That premium reflects a durable franchise our peer-anchored $292 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $440–$820. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 51% near-term growth, ahead of our forecast of about 34%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, weak execution quality.
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Industrials names rated weak grew net income 58% of the time over the next year (vs 62% for the rest of the cohort, n=3678).
Over the trailing year it converted 0.75x of net income into operating cash flow. Historically, Industrials names rated fragile grew net income 56% of the time over the next year (vs 60% for the rest of the cohort, n=3333).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.81 → $1.83 (+0.7% / 30d). 10 raised, 8 cut, 18 covering analysts.
0 upgrades, 0 downgrades / 30d. 90% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$218.
How much price usually moves either way.
On a bad day, this stock has moved -$597.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,028.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This may show that Axon's growth is slowing. This could hurt investor confidence.
Confirms:Q2 2026 revenue growth reported below 27%.
Disproves:Q2 2026 revenue growth reported at or above 30%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for AXON yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
in this report on Form 8-K is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$440.00 – $820.00 (median $650.00) · 10 analysts · as of 2026-05-08
Looks more expensive than peers.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Aerospace & Defense.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
AXON Axon Enterprise | Typical Show detailsSector percentile: 55 of 100 | expensive | elevated |
GE GE Aerospace | Typical Show detailsSector percentile: 68 of 100 | full | moderate |
RTX RTX Corporation | Above typical Show detailsSector percentile: 72 of 100 | fair | moderate |
BA Boeing | Below typical Show detailsSector percentile: 18 of 100 | expensive | moderate |
LMT Lockheed Martin | Typical Show detailsSector percentile: 58 of 100 | inexpensive | moderate |
13 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Industrials names rated volatile grew net income 59% of the time over the next year (vs 59% for the rest of the cohort, n=840).
Not investment advice. As of 2026-06-12.
via XLI
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Axon aims to achieve revenue growth of 30% to 32% for the fiscal year 2026.
Axon aims to maintain an Adjusted EBITDA margin of 25.5% for the fiscal year 2026.
Axon plans to manage capital expenditures within the range of $160 million to $190 million for 2026.
Why it matters: A drop in margin may show rising costs. This can hurt profit expectations.
Confirms:Adjusted EBITDA margin is less than 25.5%.
Disproves:Adjusted EBITDA margin is at or above 25.5%.
Why it matters: This may show that demand for Axon's products is weak. This can hurt future revenue.
Confirms:Future contracted bookings growth is below 20% year over year.
Disproves:Future contracted bookings growth reported at or above 30% year over year.
Director — Matthew McBrady: Mr. McBrady will not stand for re-election as a director.
Director — Julie Anne Cullivan: Ms. Cullivan will not stand for re-election as a director.
in this report on Form 8-K is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Other Events Pursuant to a notice of redemption dated December 18, 2025, in respect of the 0.50% convertible senior notes due 2027 (the “Convertible Notes”) of Axon Enterprise, Inc. (the “Company”), the Company redeemed $840,000 aggregate principal amount of Convertible Notes on February 10, 2026, with cash, at a redemption price equal to 100% of the principal amount thereof, together with accrued and unpaid interest to, but excluding, February 10, 2026. Further, pursuant to the notice of red…